Company intelligence / Profile preview
Talphera
San Mateo, California, United Statestalphera.com ↗
- Ownership
- Public · TLPH
- Employees
- ~14
- Development stage
- Commercial
01
Overview
Talphera’s lead product candidate is Niyad, a lyophilized formulation of nafamostat as an anticoagulant for extracorporeal circuits in dialysis. Other pipeline assets include LTX‑608 for inflammatory and viral conditions, and ready-to-use prefilled syringes such as PFS‑02 and Fedsyra targeting hypotension and clotting disorders. The company divested its FDA-approved acute pain drug DSUVIA in 2023 but retains royalty rights on future sales[1][3][4].
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularHematologyInfectious Diseases
- Modalities
- Small moleculeDevice (prefilled syringe products)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
none disclosed post-rebranding; previously partnered with Alora Pharmaceuticals via DSUVIA divestment[1]
04
Financials
- Market cap
- $61.8M
- Total revenue
- $0
- Enterprise value
- $44.7M
Beyond the preview
Go deeper on Talphera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Talphera.